Ab&B Bio-Tech

Ab&B Bio-Tech Co., Ltd. has a registered capital of 360 million RMB, with a construction area of approximately 170 mu. The company's first production park project is invested at 1 billion RMB, the second production park project at 2 billion RMB, and the third production park project at 600 million RMB. It is committed to the research, registration, industrial production, and sales of innovative human vaccines, targeting international standards and conducting independent innovation research. The Shanghai/Taizhou R&D center and pilot platform are advancing multiple vaccine pipelines simultaneously, including viral vaccines, bacterial vaccines, conjugate vaccines, recombinant subunit vaccines, and mRNA vaccines. Currently, the company’s quadrivalent influenza virus subunit vaccine (for ages 3 and above) has been marketed. The quadrivalent influenza virus subunit vaccine (for ages 6-36 months) has completed Phase III clinical trials and entered the NDA registration and production reporting stage. The 23-valent pneumococcal polysaccharide vaccine has completed Phase I clinical trials, while the freeze-dried human rabies vaccine (human diploid cell) is undergoing Phase I clinical trials. Multiple academic achievements have been published in the authoritative international journal Vaccine and have been continuously cited in recent annual editions of China’s Technical Guidelines for Influenza Vaccine Prevention and Vaccination.